Treatment of Fulminant Clostridioides difficile Infection Supported by Hypotension, Shock, Ileus, or Megacolon

Clinical Scenario

This protocol addresses fulminant Clostridioides difficile infection (CDI) — a severe presentation recognised by specific clinical findings that distinguish it from non-fulminant disease and drive a more intensive treatment approach.

Defining Features of Fulminant CDI

The fulminant classification is supported by the presence of one or more of the following:

Hypotension or shock
Ileus
Megacolon

Treatment Approach

Management of fulminant CDI involves antibiotic therapy delivered through multiple routes, with the specific combination and delivery method adjusted according to the presence of ileus. The complete regimen — including route selection, combination strategy, and sequencing — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciab549

Definition of fulminant CDI is supported by: Hypotension or shock, ileus, megacolon.

The previous iteration of the guidelines also recommends vancomycin (500 mg 4 times daily orally or by nasogastric tube) rather than fidaxomicin for treatment of fulminant (previously known as severe, complicated) CDI.

Vancomycin 500 mg 4 times daily by mouth or by nasogastric tube. If ileus, consider adding rectal instillation of vancomycin. Intravenously administered metronidazole (500 mg every 8 hours) should be administered together with oral or rectal vancomycin, particularly if ileus is present.

View source ↗